ArticleProceedings of the National Academy of Sciences of the United States of America2008
Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 67 citations in OpenAlex.
- A unifying theory of brain signaling and its possible role in acquired chronic disease.Frontiers in neuroscience · 2026Article
- A fusion-based multiomics classification approach for enhanced gene discovery in non-small cell lung cancer.Bioinformatics advances · 2026Article
- Exploring the shared genetic architecture between leukocyte telomere length and renal cell carcinoma: a cross-trait analysis.Discover oncology · 2025Article
- Therapeutic Potential of Quadrigemine I Against Lymphoma: Mechanistic Insights from Cell Lines and Xenograft Models Demonstrating DNA Damage, Oxidative Stress, and Pathway Regulation.International journal of molecular sciences · 2025Article
- Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis.Heliyon · 2024Article
- Investigating the shared genetic architecture between breast and ovarian cancers.Genetics and molecular biology · 2024Article
- A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD).Cancer cell international · 2021Article
- Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Article
- Anabolic and Pro-metabolic Functions of CREB-CRTC in Skeletal Muscle: Advantages and Obstacles for Type 2 Diabetes and Cancer Cachexia.Frontiers in endocrinology · 2019Review
- Identification of novel enriched recurrent chimeric COL7A1-UCN2 in human laryngeal cancer samples using deep sequencing.BMC cancer · 2018Article
- Evaluation of the Ki-67 Proliferation Index and Urocortin Expression in Women with Ovarian Endometriomas.The Eurasian journal of medicine · 2017Article
- Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.The American journal of pathology · 2016Article
- Article
- Corticotropin Releasing Hormone and Urocortin 3 Stimulate Vascular Endothelial Growth Factor Expression through the cAMP/CREB Pathway.The Journal of biological chemistry · 2015Article
- TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma.Frontiers of medicine · 2015Article
- Multi-facets of Corticotropin-releasing Factor in Modulating Inflammation and Angiogenesis.Journal of neurogastroenterology and motility · 2015Article
- Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis.Intestinal research · 2014Review
- Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.BMC cancer · 2013Article
- Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.Acta pharmacologica Sinica · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The corticotropin-releasing factor (CRF) receptor CRFR2 is expressed widely in peripheral tissues and in the vasculature, although its functional roles in those tissues have only recently begun to be elucidated. Previously we found that genetic deletion of CRFR2 resulted in profound postnatal hypervascularization in mice, characterized by both an increase in total vessel number and a dramatic increase in vessel diameter. These data strongly suggested that ligands for CRFR2 act to limit tissue vascularity, perhaps as a counterbalance to factors that promote neovascularization. Urocortin 2 (Ucn2) is a specific ligand for the CRFR2. We hypothesized that activation of CRFR2 by Ucn2 might thus suppress tumor vascularization and consequently limit tumor growth. Here, we show that viral-mediated expression of Ucn2 strikingly inhibits the growth and vascularization of Lewis Lung Carcinoma Cell (LLCC) tumors in vivo. Further, we found that this effect on tumor growth inhibition was independent of whether exposure to Ucn2 occurred before or after establishment of measurable tumors. In vitro, Ucn2 directly inhibited the proliferation of LLCC, suggesting that the tumor-suppressing effects of CRFR2 activation involve a dual mechanism of both a direct inhibition of tumor cell cycling and the suppression of tumor vascularization. These results establish that Ucn2 inhibits tumor growth, suggesting a potential therapeutic role for CRFR2 ligands in clinical malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.